LCZ696G

Drug Novartis Pharma AG
Total Payments
$174,400
Transactions
54
Doctors
9
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2018 $55,878 27 8
2017 $118,522 27 6

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $148,114 17 84.9%
Consulting Fee $15,092 4 8.7%
Travel and Lodging $9,979 13 5.7%
Food and Beverage $1,215 20 0.7%

Payments by Type

Research
$148,114
17 transactions
General
$26,286
37 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
CLCZ696G2301 Novartis Pharma AG $148,114 2

Top Doctors Receiving Payments for LCZ696G

Doctor Specialty Location Total Records
Unknown — Boston, MA $136,109 13
, M.D Cardiovascular Disease Durham, NC $15,555 10
, MD Cardiovascular Disease Saint Louis, MO $10,622 5
, MD Interventional Cardiology Dallas, TX $8,959 4
, MD Internal Medicine Mpls, MN $1,470 1
, M.D Cardiovascular Disease Boston, MA $793.15 10
, MD Cardiovascular Disease Cleveland, OH $324.24 2
, MD Cardiovascular Disease Boston, MA $256.32 4
, MD Cardiovascular Disease Boston, MA $166.40 3
, MD Emergency Medicine Cleveland, OH $145.70 2

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $174,400
  • Total Doctors 9
  • Transactions 54

About LCZ696G

LCZ696G is a drug associated with $174,400 in payments to 9 healthcare providers, recorded across 54 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.

Payment data is available from 2017 to 2018. In 2018, $55,878 was paid across 27 transactions to 8 doctors.

The most common payment nature for LCZ696G is "Unspecified" ($148,114, 84.9% of total).

LCZ696G is associated with 1 research study, including "CLCZ696G2301" ($148,114).